SEC Company Response from RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643) (RLMD) — Oct 30, 2019
RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643)
Date: Oct. 30, 2019 · CIK: 0001553643 · Accession: 0001213900-19-021477
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234262
Letter
RELMADA THERAPEUTICS, INC.
880 Third Avenue, 12th Floor
New York, New York 10022
October 30, 2019
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attention: Ada D. Sarmento and Celeste Murphy
Re: Relmada Therapeutics, Inc.
Amendment No. 1 to Registration Statement on Form S-3
File No. 333-234262
Ladies and Gentlemen:
Relmada Therapeutics, Inc.’s (the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. Eastern time, Thursday, October 31, 2019, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”).
In connection with the Company’s request for acceleration of effectiveness of the above-referenced Registration Statement, the Company acknowledges the following:
(1) Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
(2) The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(3) The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
RELMADA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
RELMADA THERAPEUTICS, INC.
880 Third Avenue, 12th Floor
New York, New York 10022
October 30, 2019
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attention: Ada D. Sarmento and Celeste Murphy
Re:
Relmada Therapeutics, Inc.
Amendment No. 1 to Registration Statement on Form S-3
File No. 333-234262
Ladies and Gentlemen:
Relmada Therapeutics, Inc.’s (the “Company”)
hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effectiveness
of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. Eastern
time, Thursday, October 31, 2019, or as soon thereafter as practicable, or at such later time as the Company or its counsel may
orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission
(the “Commission”).
In connection with the Company’s request
for acceleration of effectiveness of the above-referenced Registration Statement, the Company acknowledges the following:
(1)
Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose
the Commission from taking any action with respect to the filing;
(2) The action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
(3)
The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.
Very truly yours,
RELMADA THERAPEUTICS, INC.
By:
/s/ Sergio Traversa
Name: Sergio Traversa
Title: Chief Executive Officer